CTAD Thursday December 5.

To start the day, Biogen will present Aducanumab Phase 3 results at 8am Pacific with a live webcast. Biogen will also hold an investor Q&A call at 2pm Pacific.

Later that day at around 4:30pm Pacific, Dr. Jeffrey Cummings presents the BETonMACE cognition sub-study during the session "Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies." 

Dr. Cummings' presentation is titled "Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease."

Right before Dr. Cummings is Dr. Kulikowski from Resverlogix presenting "The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease."

Perhaps a Resverlogix company webcast that day or the next. They also have a poster on Friday/Saturday entitled "Epigenetic Modulator Apabetalone Inhibits Monocyte Adhesion To Brain Endothelial Cells By Downregulating Key Neuroinflammation Markers In Vitro And In Vivo."

Thursday December 5th will be a huge day for news from CTAD. Probably not many have Resverlogix/Apabetalone/BETonMACE on their radar. Hopefully some good news will change that and give the media something other than Biogen/Aducanumab to report on.

BearDownAZ